QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

Original from: Waters · Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters’ proven execution model · Doubles Wate..

Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.

Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative. This collaboration aims to accelerate and simplify workflows for throughput NGS library preparation by delivering validated automation protocols for ClaretBio’s SRSLY® and REALLY™ product lines on Hamilton’s NGS STAR liquid handling platforms.

The National Medical Products Administration (NMPA) of China has introduced a series of strategic measures to accelerate the development of new-quality productivity in the high-end medical device sector.

Original from: Access Newswire VieCure Inc., pioneer of an intelligent cancer care ecosystem that democratizes precision oncology for community-based practices, today announced a strategic partnership wit..

The UK government said Thursday that it will align its regulations on high-risk in vitro diagnostic devices that are sold in Great Britain to align with EU specifications and repeal regulations specific to COVID-19 tests.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a new initiative with NOWDiagnostics (NOWDx), a leader in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, to expand access to rapid syphilis testing. The companies will distribute First to Know® Syphilis Test kits at no cost to select community-based public health organizations across the country.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

Leinco Technologies, a leading global provider of in vitro diagnostic (IVD) raw materials, today announced the acquisition of BioClin, Inc.’s proprietary antibody clones used as IVD raw materials. This strategic partnership significantly expands Leinco’s portfolio of critical reagents for endocrine hormone research and diagnostic assays.

Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.

The POCT Market 1. International Market Conditions The POCT market is large and has enjoyed sound growth. From 2008 to 2018, the sales volume of the global POCT market doubled, with an average annu..

Siemens Healthineers Officially Launches First APAC Production Line for Laboratory Diagnostics Equipment Siemens Healthineers' first domestically produced high-end laboratory diagnostics system—the Atel..

Noul said it has signed a memorandum of understanding (MOU) with Seegene Brazil to introduce its AI-based cervical cancer diagnostic solution, miLab CER, to the Brazilian market.

MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira’s Multiplo® TP/HIV rapid test for use as a self-test in Canada.